Bristol-Myers Squibb Board Elects Charles Bancroft Chief Financial Officer

Bristol-Myers Squibb Board Elects Charles Bancroft Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company's Board of Directors has elected Charles Bancroft chief financial officer effective April 8, 2010. In this role, Mr. Bancroft will be responsible for directing and managing the company's fiscal operations and the global finance organization. Mr. Bancroft has been serving as the company's acting CFO since January 1, 2010. He will report to Lamberto Andreotti, president and chief operating officer, and chief executive officer designate.

"The Board of Directors, Jim Cornelius and I have great confidence in Charlie's ability to provide the financial stewardship needed to help drive shareholder value," said Mr. Andreotti. "His tenure with Bristol-Myers Squibb has been marked by strong leadership and depth of experience in finance, earning him trust and respect from his peers across all functions and within the entire finance organization."

Mr. Bancroft joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.